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We propose a series of simulations about the potential use of Boron isotopes to trigger neutron-free (aneutronic) 
nuclear reactions in cancer cells through the interaction with an incoming energetic proton beam, thus resulting in 
the emission of characteristic prompt gamma radiation (429 keV, 718 keV and 1435 keV). Furthermore assuming 
that the Boron isotopes are absorbed in cancer cells, the three alpha-particles produced in each p-
11
B aneutronic 
nuclear fusion reactions can potentially result in the enhancement of the biological dose absorbed in the tumor 
region since these multi-MeV alpha-particles are stopped inside the single cancer cell, thus allowing to spare the 
surrounding tissues. Although a similar approach based on the use of 
11
B nuclei has been proposed in [1], our work 
demonstrate, using Monte Carlo simulations, the crucial importance of the use of 
10
B nuclei (in a solution containing 
also 
11
B) for the generation of prompt gamma-rays, which can be applied to medical imaging. In fact, we 
demonstrate that the use of 
10
B nuclei can enhance the intensity of the 718 keV gamma-ray peak more than 30 times 
compared to the solution containing only 
11
B nuclei. A detailed explanation of the origin of the different prompt 
gamma-rays, as well as of their application as real-time diagnostics during a potential cancer treatment, is here 
discussed.   
Keywords: neutron-free nuclear reactions, prompt gamma-ray imaging, cancer treatment, Monte Carlo simulations.  
 
 
1. Introduction 
 
11
B(p nuclear-fusion was investigated for the first time in 1930s by Oliphant and 
Rutherford, who demonstrated that an energetic proton beam interacting with 
11
B nuclei, can 
trigger the following nuclear reaction [2]: 
 
11B + p → 3 + 8.7 MeV                    -1- 
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Theoretical calculations, confirmed by experimental measurements have shown that the channel 
with highest cross-section of this reaction occurs with protons having energies around 600-700 
keV. The result of such reaction main channel is the generation of three alpha-particles with 
typical energies between 2.5 MeV and 5.5 MeV, with a maximum at about 4.5 MeV [3, 4, 5, 6 
and 7]. The main advantage of such reaction is that it does not involve neutron generation and its 
products (alpha particles) can be easily completely stopped in a mm-thick layer of any solid 
material. For these reasons the proton-Boron nuclear fusion reaction has been actively 
investigated by several research groups for energy production [8, 9 and 10]. In the last decade a 
renewed interest on this topic has been shown through the possibility to trigger such nuclear 
reactions by using high power pulsed laser interacting with solid B-enriched targets [11, 12, 13, 
14, 15, 16, 17 and 18].  
Charged energetic particles are routinely used in medicine, in particular in cancer therapy. 
Currently hadron-therapy is becoming one of the most important medical procedures to treat 
solidified tumors instead of traditional radiotherapy treatments [19, 20 and 21]. However, further 
improvements can be carried out not only in terms of overall cost of hadron-therapy centers, in 
order for them to proliferate, but also in terms of improvement of the overall treatment quality 
based on the tumor type and on its location in the human body. Although several candidates have 
been considered for this treatment technique (especially in terms of ion species), at the moment 
mainly protons and carbon ions have achieved very satisfactory clinical results and are routinely 
used for cancer treatment. The main advantage of hadron-therapy compared to traditional 
radiotherapy consists in the fact that charged particles release most of their energy in a few 
millimeters close to the end of their penetration range (so-called Bragg peak region). Such 
important characteristics allow to damage critically only the tumor cells and limit the interaction 
with the healthy tissues surrounding the tumor region. Moreover, an evident enhancement of the 
Relative Biological Effectiveness (RBE) has been demonstrated in the case of carbon ions 
compared to protons, thus resulting in a more efficient treatment for most of the radio resistant 
tumors [22, 23, 24 and 25]. On the other hand, by using carbon ions, issues connected with 
projectile and target nuclear fragmentation can arise, thus leading to unwanted dose deposition 
beyond the Bragg peak caused by the lightest fragments. Moreover, nuclear fragmentation of the 
resulting mixed field, increases the uncertainty of the biological dose, which is ultimately 
released into the cancer tissues. 
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Alternative techniques for cancer therapy are being considered in order to enhance the efficiency 
of such treatment. For instance, nuclear reactions involving the interaction of thermal neutrons 
and 
10
B nuclei are already used in medicine for cancer treatment in the so-called Boron Neutron 
Capture Therapy (BNCT) technique [26, 27 and 28]. In BNCT a solution containing 
10
B is 
injected into the human body and is absorbed in the tissues surrounding the tumor region. The 
used nuclear reaction is the following: 
 
10
B + nth → [
11
B]
*
 →  + 7Li + 2.3 MeV                      -2- 
 
which gives as final product an energetic alpha-particle. The produced alpha-particles are mainly 
localized in the tumor region due to their short propagation length and high stopping power, 
leading to a more efficient interaction with the tumor cells and their subsequent damage. 
However, unlike the classical hadron-therapy where a charged particle beam delivers a dose 
according to the Bragg-peak curve, in BNCT a neutron beam is slowly attenuated in the human 
body, thus healthy tissues lying along the neutron beam injection path are unavoidably exposed 
to relevant neutron doses before the final interaction of the neutrons with the boron enriched 
tumor cells. Furthermore, BNCT requires a so-called epithermal neutron beam which, in turn, 
requires sophisticated experimental devices for its generation (including shielding barriers for the 
patients), currently making BNCT very limited in terms of accessibility. 
Recently a new approach, where the alpha-particles are generated by the interaction of a proton 
beam with 
11
B nuclei, has been proposed (not yet experimentally demonstrated) as Proton Boron 
Fusion Therapy (PBFT) [1]. As described in [1] in such scheme a solution containing 
11
B nuclei 
should be injected into the human body and, due to the interaction with an incoming proton, the 
proton-boron nuclear fusion reaction takes place and generates three alpha-particles, which can 
potentially destroy cancer cells more efficiently compared to a conventional proton therapy 
treatment. Moreover, the authors of [1] propose the generation and measurement of characteristic 
gamma-rays at 718 keV as real-time imaging technique. In the following we will firstly 
demonstrate that the proton-Boron nuclear fusion reaction using 
11
B nuclei does not produce 
prompt gamma rays and, as a consequence, does not have an “online” imaging capability. 
However, we will show that the combination of 
11
B and 
10
B can be used for this purpose. 
Moreover, depending on the tumor type and location, the concentration of Boron atoms in the 
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solution, as well as the relative concentration of 
11
B and 
10
B isotopes, has to be optimized. In 
fact, while tumors with larger size, more resistant and closer to sensitive tissues in the human 
body would benefit from a higher concentration of 
11
B compared to 
10
B nuclei, smaller, non-
radiation resistant, deeper-seated tumors would need a higher concentration of 
10
B compared to 
11
B in order to compensate the higher absorption in the human body of the characteristic prompt 
gamma radiation, ultimately to be used for real-time imaging. 
Furthermore, the source of the physical dose enhancement reported in [1], identified as main 
feature of PBFT, is incorrect. In fact, as it will be discussed in detail below, the treatment 
enhancement reported in [1] cannot be ascribed to a relevant increase of the physical dose 
(depicted in Fig.2 and Fig.3 of [1]) and, in addition, there is no prompt gamma radiation 
generated in the p-
11
B fusion nuclear reaction at 718 keV claimed in [1]. Furthermore, while in 
[1] only the use of the proton-boron nuclear fusion reaction is discussed, in the present work 
additional nuclear reactions, occurring due to the presence of 
10
B nuclei, are proposed for the 
generation of characteristic prompt gamma-rays. 
An innovative scheme for simultaneous prompt gamma ray imaging and enhanced hadron-
therapy using neutron-free nuclear reactions is presented and discussed in this work through the 
use of Monte Carlo simulation outputs. 
 
2. Methods 
 
The interaction of protons with 
10
B nuclei triggers aneutronic nuclear reactions generating 
characteristic prompt gamma-rays which can be used for a real-time monitoring of the treatment 
and potentially for a sort of dynamic treatment with a feedback control based on real-time dose 
measurement. 
The characteristic prompt gamma-ray peaks due to the interaction of the 
10
B nuclei with the 
incoming energetic protons are peaked at 429 keV, 718 keV and at 1435 keV. The peak at 429 
keV is ascribed to the 
10
B (p, α) 7Be nuclear reaction. The peak at 718 keV is mainly ascribed to 
the inelastic scattering of the proton, 
10
B (
10
B* (p,p`) 
10
B), but it can also be produced from the 
10
B (p,n) 
10
C reaction and the consequent 
10
C + decay but with a much less cross section (see 
Fig.3) into the 
10
B* (not resulting in a prompt gamma ray emission). The peak at 1435 keV is 
due to the 
10
B (p,p`) 
10
B* nuclear reaction which is generated when the 
10
B* nuclei decay from 
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the 2.15 MeV level to the 718 keV level. All these peaks (excluding the 718 keV produced in the 
10
C + decay) are prompt gamma-rays which can be used for real-time measurements. 
The 
11
B nuclei interacting with protons can trigger the 
11
B (p,2n) 
10
C nuclear reaction + 
decaying in 
10
B* and emitting a gamma-ray at 718 keV, but the cross-section of such reaction is 
very low compared to the cross-sections of the other reactions with 
10
B nuclei above described. 
Moreover the gamma-rays produced in such reaction are not prompt, thus the specific reaction is 
not useful for a real-time measurement. Additional details about these reactions will be given in 
the section “Results and discussions” and in Fig.3. 
The proposed treatment procedure benefits from both proton therapy, since protons are mainly 
used as projectiles to trigger the nuclear fusion reaction, and heavier ion therapy, since alpha-
particles generated in the nuclear fusion reactions have a higher LET (Linear Energy Transfer) 
and cause more efficient damages in the single cell. 
It is worth highlighting that the presence of an optimized mixture of 
10
B and 
11
B is crucial for the 
method hereby described. In fact, the 
11
B nuclei are important for triggering the p-
11
B nuclear 
fusion reaction (enhanced treatment capability), while the 
10
B nuclei are important for the 
generation of prompt gamma-rays (real-time imaging capability), thus allowing to carry out a 
potential dynamic treatment. Moreover, in order to maximize the effects of the cancer treatment 
and the imaging capability, the optimization of the ratio 
10
B/
11
B is crucial. On the one hand, for 
superficial tumors it is more convenient to increase the 
10
B concentration with respect to the 
11
B 
one in order to maximize the production of gamma prompt peaks. The presence of such 
exclusive peaks, will improve the quality of the beam imaging process. On the other hand, for 
tumor depth larger than 10 cm of soft tissue, the gamma attenuation will reduce the total amount 
of detectable gammas, thus it will be more convenient to increase the percentage of 
11
B with 
respect to 
10
B.    
Fig.1a shows a conceptual sketch of the system used for a potential simultaneous cancer 
treatment and diagnostic approach (gamma-ray detector, proton beam, patient positioning 
system). The same figure shows the geometry used for our numerical simulation performed by 
using the MCNPX 2.7 Monte Carlo code [29], along with details of the two different planes, xy 
in b) and xz in c). 
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A water cylinder (here labelled as H2O) with density of 1.01 g/cm
3
, with a total length of 3.5 cm 
and with a diameter of 6 cm (simulating the human body) is irradiated by a mono-energetic 
proton beam with energy of 60 MeV, placed along the z axis. In order to simulate the cancer 
region surrounded by the solution containing B atoms, a small cylinder (3 mm long and 4 cm 
wide) is placed in the Bragg peak region in the position between 2.9 and 3.2 cm within the water 
Plane xy Plane xz 
proton beam 
b) c) 
a) 
Proton beam 
Depth 
Gamma detector 
Water 
phantom 
Fig.1: setup employed for MCNPX simulations. a) is a sketch of the overall system. b) and c) are 
respectively, sketches showing the xy and xz planes. The cylindrical shell in gray represents the Ge gamma-
rays detector, the light blue shape is the water phantom including the B isotopes doped region (in red). The 
incoming proton beam is represented in green.  
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cylinder. As real-time diagnostics a Ge gamma-ray cylindrical-shell detector with internal 
diameter of 26 cm and thickness of 4 cm is used. The Ge detector is placed around the water 
phantom covering the whole sample in order to maximize the signal coming out of the irradiated 
sample.  
Gamma ray characteristic emission peaks have been studied in different conditions of Boron 
concentration. In particular, we studied three ‘pure’ configurations where only 10B, 11B or natural 
B have been considered (here respectively labelled as B10, B11 and B) and one water-based 
solution containing 1% of 
11
B, here labelled as B11(1%). The isotopic composition of the natural 
Boron is 
10
B at 20% and 
11
B at 80%. We have also studied a configuration containing only water 
(in the text labelled as H2O). 
Our numerical investigation allowed explaining the origin of all characteristic gamma-ray peaks 
in the energy range 200 keV - 1.5 MeV. For our simulations the “ftally 8” (energy distribution of 
pulses created in the detector by radiation) has been used. In the second part of the simulation 
study, the dose released by the energetic proton beam in H2O was also calculated to investigate 
how the Bragg peak can change intensity and position within the sample, according to different 
concentrations of 
11
B within this region. In order to perform such simulation the “ftally 6” 
(energy deposition averaged over a cell given in MeV/g) has been used. In this case H2O was 
divided in small cylinders with length of 0.1 mm each. The small 
11
B cylinders had the same 
length of the water cylinders (0.1 mm) and 20 of them were positioned in the Bragg peak region.  
The proton and alpha particle energy deposition in H2O was also studied by using the “tmesh 3” 
(MeV/cm
3
/source particles). The “tmesh 1” (flux given in number of particles per cm2) was used 
to calculate the alpha-particle and proton distributions through the depth of the sample. A very 
high statistics of injected protons (6*10
8
 proton/simulation) has been used for each of these 
simulations. Default dataset for the cross-sections given by MCNPX were kept without changes 
to avoid unrealistic results arising from potential errors in the simulation modelling. For more 
detailed information about the meaning of ftallyes and tmeshes one can refer to the MCNPX 
2.7.0 manual. 
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3. Results and discussions 
 
The first investigation performed through MCNPX simulations provides a preliminary idea of 
the characteristic gamma-rays which could come out of the human body during a potential 
cancer treatment. In these preliminary simulations gamma-ray spectra up to 1.5 MeV with a 
resolution in energy of less than 1 keV are obtained. A particular attention is given to the 
following gamma-ray peaks: 429 keV, 718 keV and 1435 keV. A Ge gamma-ray cylindrical-
shell detector is used in the simulations in order to maximize the signal generated from the 
irradiated samples. The different samples (H2O, B10, B11 and B) are irradiated by a mono-
energetic proton beam of 60 MeV. Results of the emitted gamma-rays with different samples are 
shown in Fig.2 a) for H2O and B10 (on the top of the figure),
 
B11 (on the middle of the figure) 
and B (on the bottom of the figure), respectively. 
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Fig.2: a) gamma-ray spectra emitted in the case of the sample H2O and B10 (on the top of a), 11B (on 
the middle of a) and B (on the bottom of a). Detailed comparison of the gamma-ray peaks at 429 keV 
b), at 718 keV c) and at 1435 keV d) are also here showed. 
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The first important result is evident from the H2O spectrum where there is no presence of 
characteristic gamma-ray peaks concerning the mentioned above. The 511 keV peak comes from 
the positron annihilation followed to the electron-positron pair production in the target material 
and in the detector itself. In the case of B10 (red curve) there are three different clear prompt 
gamma-ray peaks: 718 keV (the most intense), 429 keV and 1435 keV. A completely different 
spectrum is reported in the middle part of Fig.2a for the gamma-ray emission from B11 (blue 
curve). Here only the peak at 718 keV is identified, however the relative peak intensity is much 
lower compared to B10 (more than a factor 30). Substantial differences in the gamma-ray 
spectrum features are shown when comparing the case of B10 and the case of B11. In the latter 
case there is no presence of gamma peaks at 429 keV and at 1435 keV, only the peak at 718 keV 
appears, although the relative intensity is very low compared to B10. This is an important point 
since the presence of both boron isotopes (
11
B and 
10
B) in an optimized relative percentage 
(depending on the tumor) is necessary for the proposed simultaneous imaging and treatment 
technique, differently than what stated in [1] where only 
11
B nuclei are used for the proposed 
gamma-ray imaging. 
Fig.2a (bottom part) shows the results obtained with B (green curve). These results are in 
agreement with what discussed above in terms of gamma ray peaks at 429 keV, 718 keV and 
1435 keV, which are present with different relative intensities, thus showing an intermediate 
behavior compared to B11 and B10. Fig.2 shows also the comparisons among the gamma-ray 
peaks at 429 keV (b), 718 keV (c) and 1435 keV (d) for B10 (in red), B11 (in black) and B (in 
green), respectively. The same comparison is reported in Table I, where the peak values are 
normalized to the 718 keV peak intensity recorded in the case of the B10 sample.  
Several important conclusions can be anticipated from a first comparison among the different 
simulated spectra. All the above described characteristic gamma-ray peaks are mainly ascribable 
to the presence of 
10
B nuclei. The major peak at 718 keV is present for all the different simulated 
samples, however in the case of B11 the intensity of the gamma-ray signal is more than 30 times 
lower than in the case of B10. From Table I it is also clear that in the case of B (containing 20% 
of 
10
B nuclei) the gamma-ray peak at 718 keV is about 7 times more intense than the B11 case. 
This is a very important result because it shows that it is possible to modify and optimize the 
intensity of the detected gamma-ray peaks by changing the relative concentration of 
10
B and 
11
B 
10 
 
nuclei in the injected solution. The minor gamma-ray peaks (429 keV and 1435 keV) are present 
only in the cases of B10 and B. 
 
 
 
 
 
 
Beside the outputs of our numerical simulations in terms of gamma-ray spectral line intensities, 
it is important to explain the origin of the above mentioned characteristic gamma ray peaks.  In 
the case of B10 the following reaction is responsible of the emission of gamma-rays at 718 keV: 
 
10
B (p,p`) 10B                                 -3- 
 
This is an aneutronic nuclear reaction, with a non-negligible cross-section for energies of a few 
MeV, based on the inelastic scattering of the 
10
B nuclei with the incoming protons [30]. 
The following nuclear reactions are also possible: 
10
B (p,n) 
10
C and 
10
C + decay , evolving into 
a 
10
B* exited state and then emitting a gamma-ray at 718 keV [30 and 31]. However, only the 
inelastic reaction -3- leads to a prompt gamma-ray peak, while the other reactions do not 
generate prompt gamma radiation.  
Furthermore, the interaction of the protons with 
10
B nuclei can also trigger another nuclear 
reaction: 
 
10
B (p,) 7Be                                -4- 
 
where the final result is a prompt gamma-ray emission at 429 keV [32].  
Target Intensity at 429 keV Intensity at 718 keV Intensity at 1435 keV 
B 12.4 22 3.8 
10
B 49.6 100 13.8 
11
B NA 3.1 NA 
Table I: normalized gamma-ray peaks intensity at 429 keV, 718 keV and 1435 keV for the different 
investigated cases (B, B10 and B11). Here values are normalized respect to the value of the 718 keV 
gamma-rays peak in the sample B10. 
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For a full explanation of the gamma spectrum obtained in the simulations for the B11 sample, the 
following series of nuclear reactions have been identified: 
11
B (p,2n) 
10
C, followed by a + decay 
of 
10
C, thus populating the 
10
B* exited state and finally emitting a gamma-ray at 718 keV [33]. It 
is worth mentioning that the cross-section of 
11
B (p,2n) 
10
C is negligible compared to 
10
B 
(p,n)
10
C cross section for a proton energy of a few MeV. This can explain the large difference in 
terms of peak intensity for the 718 keV gamma radiation shown as a result of our numerical 
simulations (30 times lower for B11 compared to B10). In conclusion, the above identified 
nuclear reactions can fully explain the origin of the gamma-ray peaks shown by our Monte Carlo 
simulations.  
Additional details are shown in Fig.3 where the rates of the 718 keV gamma-ray peaks for 
different reactions are compared. The relative reaction rate for the inelastic scattering and for the 
10
B (p,n) 
10
C nuclear reaction are compared. In the area of interest within the Bragg peak 
(represented with a blue dotted region in Fig. 3) the relative rate of 
10
B (p,n) 
10
C is less than 10% 
compared to the inelastic scattering. This clearly explains that the main contribution of the 718 
keV peak is ascribable to the 
10
B (p,p`) 10B inelastic scattering. 
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Fig.3: comparison of the 718 keV characteristic gamma-ray generation 
rate for different nuclear reactions: 
10
B (p,p`) 
10
B* (in black) and 
10
B 
(p,n) 
10
C (in red). 
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The second part of this numerical work supports the proposed new tumor treatment method. This 
study provides a different understanding of such approach with respect to the interpretation 
described in [1]. The H2O sample, irradiated with an incoming mono-energetic proton beam of 
60 MeV, is used as a reference. A preliminary study allows estimating the dose released by the 
protons in H2O, which shows the Bragg peak location at 3 cm from the sample surface. The 
reference sample is compared with the B11(1%) one, which is a realistic case considering the 
typical concentration of Boron used in the BNCT therapy. The comparison between H2O (in 
black) and B11(1%) (in red) simulation outputs is shown in Fig.4a.  
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Fig.4: relative dose released by protons within H2O (black line), B11(1%) (red line) and B11 (blue line) (a). 
The red dashed region represents the area where the 
11
B nuclei are located within the doped water phantoms. 
b) is a zoom in the depth range between 2.8 cm and 3.2 cm, showing a detail of the relative dose released by 
protons for H2O and B11(1%). Fig. 4 c) shows the relative energy deposited in B11(1%) by protons and 
alphas (black line) and only by protons (red line). 
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Here only the proton dose without the potential alpha-particle contribution is considered. The 
calculated values are normalized considering the H2O results as a reference case (100% intensity 
at the peak). A small enhancement (less than 10%) of the physical dose released within the 
Bragg peak region in the case of B11(1%) is marked in red. The position of the Bragg peak in 
both cases is practically the same. This result shows that the small enhancement in the physical 
dose observed in the case of B11(1%) is not ascribable to the alpha particles produced in the 
proton-Boron nuclear reaction, contrary to what reported in [1], however it is mainly due to the 
presence of the 
11
B atoms, which changes the composition and the density of the water phantom. 
In order to further demonstrate the previous statement, we have considered an unrealistic case 
where the concentration of 
11
B nuclei is 100% (overestimation) and the Boron density is 2.46 
g/cm
3
. The simulation results are shown in Fig.4a (the blue line shows the Bragg curve). A large 
enhancement of the Bragg peak compared to the H2O case is shown (from 100% to 180%), 
clearly demonstrating that this change is ascribable to the different density of the irradiated 
sample.  
Fig.4c shows the relative energy deposition for protons (in red) and for protons + alpha-particles 
(in black) for the B11(1%) sample. The comparison shows that the deposited energy is coming 
from the protons since the two curves are practically the same (only 0.3% of the total 
contribution is ascribable to the alpha-particles). In order to support this idea, a second set of 
simulations has been carried out (see Fig.5), where the flux (number/cm
2
) of the generated alpha-
particles (a), and protons (b), within the sample B11(1%) is estimated. In Fig. 5a the alpha-
particles yield (red line) is shown in comparison to the dose absorbed in the whole sample (black 
line). A Gaussian fit of the alpha-particles distribution was carried out (dashed black line). The 
low FHWM of the curve (1.3 mm) leads to the conclusion that the alpha-particles are confined in 
a very well localized region, thus allowing to define very precisely the position where they 
release the dose during the treatment. Another important point is that the peak of the alpha-
particles is placed approximately in the same position where the protons release their maximum 
dose (i.e. around the Bragg peak). Thus, the exact knowledge of the Bragg peak position and of 
the position of the peak of maximum alpha-particle dose release can be used to enhance the 
efficacy of the treatment. Fig.5b shows the number of protons passing through the irradiated 
sample. This plot is in agreement with the one reported in Fig.4a, showing that the amount of 
protons starts to decrease in the Bragg peak region, falling down to zero after a few mm. It is 
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important to note that the relative amount of alpha-particles (Fig. 5a) compared to protons (Fig. 
5b) is much lower (around 5 orders of magnitude). This again means that the physical dose 
enhancement close to the Bragg peak (around 10%) is mainly due to the protons and only in 
minor amount to the alpha-particles generated in the nuclear fusion reaction, differently than 
stated in [1]. We anticipate a potential higher efficacy of the treatment due to the enhancement of 
the biological damage (not mentioned in [1]) based on the fact that the alpha-particles generated 
by the p-
11
B nuclear fusion reaction practically lose all their energy (and are stopped) within the 
single cell and, moreover, have a higher LET leading to the generation of more complex 
damages inside the cell compared to protons used in conventional proton-therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moreover, although the standard proton-therapy is very efficient, a small part of the proton dose 
is in any case released to the healthy tissues surrounding the cancer cells. The approach proposed 
in this work is potentially more precise. In fact, a rough estimation indicates that 
11
B nuclei 
injected into the human body and located in the cancer cells, generate alpha-particles with energy 
of 2-5 MeV, thus having a range of penetration in the cells of less than 20 micrometers. Since the 
typical size of cancer cells is around 20-30 microns, most of the alpha-particles release their dose 
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Fig.5: alpha-particle a) and proton b) yield within the 11B(1%) sample. In a) the black curve is the proton 
dose released in the whole sample while the black dashed line is a Gaussian fit of the alpha-particle 
distribution (in red) showing the FWHM of 1.3 mm and the peak at 2.98 cm. 
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inside the cells, thus enhancing the possibility to destroy only the tumor tissues and to spare the 
healthy ones. In conclusion, our numerical investigations show that the alpha-particles coming 
from the p-
11
B aneutronic nuclear fusion reaction are generated in a very localized region 
corresponding to the maximum alpha-particle flux, thus allowing the possibility to irradiate the 
cancer region additionally in a very precise way, basically without losses outside the cancer 
region, thus avoiding damages in healthy tissues surrounding the tumor.  
 
4. Conclusions 
 
The possibility to inject into the human body a solution containing an optimized combination of 
11
B and 
10
B, which interacting with energetic protons can trigger proton boron neutron-free 
nuclear fusion reactions, has been investigated in this paper. This technique allows performing 
simultaneous real-time gamma-ray imaging and enhanced cancer treatment, thus having a very 
strong impact in medicine and in particular in cancer therapy, hence adding new features to the 
well-known and well-established proton-therapy. 
Monte Carlo simulations allowed understanding the origin of the characteristic gamma-ray line 
emission from the irradiated samples, which can be used for a real-time imaging of the treatment. 
We have pointed out that the presence of 
10
B nuclei is mandatory for the emission of such 
characteristic prompt gamma-rays (i.e. 429 keV, 718 keV and 1435 keV) and that the gamma-ray 
peak at 718 keV, ascribed to the p-
11
B fusion reaction in [1], is produced by a different nuclear 
reaction (
11
B (p,2n) 
10
C, followed by the  + decay of 10C, then evolving into the 10B* exited 
state). This reaction does not produce prompt gamma-rays and, as a consequence, cannot be used 
as a potential online imaging technique, differently than claimed in [1]. Furthermore we 
demonstrated that the intensity of the 718 keV gamma-ray peak is enhanced more than 30 times 
when using 
10
B nuclei instead of 
11
B nuclei.  
In conclusion, our numerical simulations demonstrate that the enhancement of the dose reported 
in [1] is not due to the occurrence of the p-
11
B fusion reaction but it is ascribable to the change in 
the density of the sample containing dopant nuclei. However, although the enhancement of the 
physical dose in the doped sample is negligible, if compared with a reference sample, we expect 
an increase of the biological dose due to the fact that the alpha-particles generated by the p-
11
B 
16 
 
nuclear reaction in the cancer cells lose most of their energy inside the cells themselves and have 
a higher LET compared to protons.  
For a deeper understanding of the proposed approach we are planning to perform an 
experimental campaign using a conventional accelerator which would involve both the 
investigation of prompt gamma-ray emission and the study of biological dose enhancement in 
cancer cells. 
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